Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A wearable artificial glomerulus.

M S Neff, S Sadjadi, R Slifkin

    Transactions - American Society for Artificial Internal Organs
    |January 1, 1979
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Medicaid managed care in rural areas: a ten-state follow-up study.

    Health affairs (Project Hope)·1999
    Same author

    To be or not to be: the decision to withdraw or be withdrawn from dialysis.

    American journal of kidney diseases : the official journal of the National Kidney Foundation·1999
    Same author

    Induction of bone morphogenetic protein-2 by interleukin-1 in human fibroblasts.

    Biochemical and biophysical research communications·1998
    Same author

    Phlebotomy for pulmonary edema in dialysis patients.

    Clinical nephrology·1997
    Same author

    Cisplatin-based chemotherapy in renal transplant recipients. A case report and a review of the literature.

    Cancer·1996
    Same author

    Hemodialysis and lupus nephritis in MKSAP VII.

    Annals of internal medicine·1987
    Same journal

    Is one allowed to stop artificial organs, allowing patients to die? Opposing physicians' and philosophers' views.

    Transactions - American Society for Artificial Internal Organs·1986
    Same journal

    Bicarbonate buffer for CAPD solution.

    Transactions - American Society for Artificial Internal Organs·1985
    Same journal

    Design features of serpentine tube membrane lung for ECCO2R.

    Transactions - American Society for Artificial Internal Organs·1985
    Same journal

    Can hemodialysis remove the factor that suppresses platelet cyclo-oxygenase activity in uremic patients?

    Transactions - American Society for Artificial Internal Organs·1985
    Same journal

    Extracorporeal anticoagulation using a serine protease inhibitor in hemodialysis in sheep.

    Transactions - American Society for Artificial Internal Organs·1985
    Same journal

    Local controlled-release of diphosphonates from ethylenevinylacetate matrices prevents bioprosthetic heart valve calcification.

    Transactions - American Society for Artificial Internal Organs·1985
    See all related articles

    Continuous hemofiltration is feasible for over 3 days using an Amicon 0.2 M2 hemofilter. This method produces significant ultrafiltrate without external pumps, enabling patient fluid replacement via oral intake.

    Area of Science:

    • Nephrology
    • Biomedical Engineering
    • Intensive Care Medicine

    Background:

    • Hemofiltration is a renal replacement therapy.
    • Continuous hemofiltration requires reliable access and efficient solute/fluid removal.
    • Optimizing hemofiltration protocols can improve patient outcomes.

    Purpose of the Study:

    • To assess the feasibility of prolonged daily hemofiltration.
    • To evaluate ultrafiltrate production and replacement strategies.
    • To determine effective anticoagulation methods for extended hemofiltration.

    Main Methods:

    • Utilized an Amicon 0.2 M2 hemofilter connected to an arteriovenous shunt.
    • Performed hemofiltration for 16 hours per day over 3+ continuous days.
    • Managed anticoagulation with heparin, warfarin, and cyproheptadine.

    Related Experiment Videos

  • Assessed ultrafiltrate volume and filter lifespan.

    • Main Results:

    • Hemofiltration successfully conducted for 16 hours daily for over 3 days.
    • Achieved an ultrafiltrate production rate exceeding 8 ml/min without external pumps.
    • Demonstrated filter functionality for at least 48 hours before replacement.
    • Identified effective anticoagulation regimens.

    Conclusions:

    • Prolonged daily hemofiltration is achievable with the described setup.
    • Oral electrolyte-glucose solution can replace ultrafiltrate effectively.
    • The Amicon 0.2 M2 hemofilter offers a viable option for extended use in hemofiltration.